SAGE Therapeutics (SAGE) Misses Q3 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. FIX
9. TSCO
10. BE

Go back to SAGE Therapeutics (SAGE) Misses Q3 EPS by 5c

Sage Therapeutics Announces Third Quarter 2016 Financial Results and Provides SRSE European Update

November 3, 2016 6:30 AM EDT

Positive Scientific Advice From European Medicines Agency on Development of SAGE-547 in SRSE Provides Regulatory Path in E.U.

Ongoing Phase 3 STATUS Trial Expected to be Sufficient to Support a European Marketing Authorization Application for SAGE-547 in SRSE

Eight Clinical Trials Across Pipeline Expected to Generate Top-Line Data in 2017

Moving into Next Strategic Phase - a Multi-Product, Neuropsych Development Portfolio

Conference Call Today at 8:00 AM ET

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (NASDAQ:... More